

Eurofins Viracor launches ExPeCT™ anti-CD19 (obe-cel) CAR T-cell assay

27 March 2026 | News

To advance proactive monitoring in next-generation immunotherapy



Eurofins Viracor, a leader in advanced clinical diagnostics, has announced the launch of the ExPeCT™ anti-CD19 (obe-cel) CAR T-cell assay, a cutting-edge solution designed to help clinicians monitor CAR T-cell therapy performance with validated precision and a quick turn-around-time for results.

The ExPeCT™ brand of CAR T-cell assays enables clinicians to monitor CAR T-cell expansion and persistence in real time. This non-invasive blood test delivers results in approximately 24 hours after specimen receipt, potentially helping clinicians make timely therapy decisions.

The assay was developed exclusively to test the expansion and persistence of obecabtagene autoleucel (obe-cel) CAR T-cell's - a second-generation CAR T-cell therapy.

Eurofins Viracor is a subsidiary of Eurofins Scientific (EUFI.PA), a global leader in bio-analytical testing, and one of the world leaders in genomic services.